Pedersen Rikke Nørgaard, Mellemkjær Lene, Ejlertsen Bent, Nørgaard Mette, Cronin-Fenton Deirdre P
Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Danish Cancer Society Research Center, Copenhagen, Denmark.
J Clin Oncol. 2022 May 1;40(13):1450-1463. doi: 10.1200/JCO.21.02062. Epub 2022 Feb 16.
Late breast cancer (BC) recurrence (ie, ≥ 10 years after primary diagnosis) may have a more favorable prognosis than earlier recurrence. We investigated the risk of BC death after late recurrence, identified prognostic factors, and compared survival after early and late recurrence.
Using the Danish Breast Cancer Group and other nationwide databases, we identified women with early or late BC recurrence during 2004-2018, who were alive 6 months after recurrence. We followed them until BC death, death from other causes, emigration, 10 years, or December 31, 2018, whichever came first. We calculated mortality rates (MRs) per 1,000 person-years (PY) and cumulative BC mortality, for early versus late recurrence, and by characteristics of the primary tumor and the late recurrence. Using Cox regression, we calculated adjusted hazard ratios (HRs) for BC death, accounting for death from other causes as competing risks.
Among 2,004 patients with late recurrence, 721 died of BC with a median survival time of 10 years (MR = 84.8 per 1,000 PY; 10-year cumulative mortality = 50%). Among 1,528 patients with early recurrence, 1,092 BC deaths occurred with a median survival time of 4 years (MR = 173.9 per 1,000 PY; 10-year cumulative mortality = 72%). We observed a lower hazard of BC-specific death among patients who developed late compared with early recurrence (hazard ratio = 0.72; 95% CI, 0.62 to 0.85). Advanced stage at primary diagnosis, distant metastases, adjuvant treatment for locoregional recurrence, and systemic treatment for distant recurrence were associated with increased mortality after late recurrence. Breast-conserving surgery at primary diagnosis, locoregional recurrence, and surgery for recurrence were associated with lower mortality after late recurrence.
Patients with late recurrence had more favorable prognosis than patients with early recurrence. The localization of recurrent disease was the main prognostic factor for BC death.
晚期乳腺癌(BC)复发(即初次诊断后≥10年)的预后可能比早期复发更有利。我们调查了晚期复发后BC死亡的风险,确定了预后因素,并比较了早期和晚期复发后的生存率。
利用丹麦乳腺癌组和其他全国性数据库,我们确定了2004年至2018年期间出现早期或晚期BC复发且复发后存活6个月的女性。我们对她们进行随访,直至BC死亡、其他原因死亡、移民、满10年或2018年12月31日,以先到者为准。我们计算了早期与晚期复发以及根据原发肿瘤和晚期复发特征的每1000人年(PY)死亡率(MRs)和累积BC死亡率。使用Cox回归,我们计算了BC死亡的调整风险比(HRs),将其他原因死亡作为竞争风险进行考量。
在2004例晚期复发患者中,721例死于BC,中位生存时间为10年(MR = 每1000 PY 84.8;10年累积死亡率 = 50%)。在1528例早期复发患者中,发生1092例BC死亡,中位生存时间为4年(MR = 每1000 PY 173.9;10年累积死亡率 = 72%)。我们观察到,与早期复发患者相比,晚期复发患者的BC特异性死亡风险更低(风险比 = 0.72;95% CI,0.62至0.85)。初次诊断时的晚期阶段、远处转移、局部区域复发的辅助治疗以及远处复发的全身治疗与晚期复发后的死亡率增加相关。初次诊断时的保乳手术、局部区域复发以及复发手术与晚期复发后的死亡率降低相关。
晚期复发患者的预后比早期复发患者更有利。复发性疾病的定位是BC死亡的主要预后因素。